Drugs / Ziltivekimab C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05021835 | Aug 2021 → Jun 2026 overdue | chronic kidney disease | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ziltivekimab C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05021835 ↗ |
| Route | Subcutaneous | “Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.” NCT05021835 ↗ |